Volume | 958,651 |
|
|||||
News | - | ||||||
Day High | 231.00 | Low High |
|||||
Day Low | 224.66 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Biogen Inc | BIIB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
231.00 | 224.66 | 231.00 | 225.43 | 231.99 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
24,559 | 958,651 | $ 227.11 | $ 217,722,862 | - | 189.44 - 319.76 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:52:41 | 10 | $ 227.00 | USD |
Biogen (BIIB) Options Flow Summary
Biogen Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
32.77B | 145.36M | - | 9.84B | 1.16B | 7.99 | 28.22 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Biogen News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 219.50 | 237.41 | 218.025 | 230.44 | 1,188,806 | 5.93 | 2.70% |
1 Month | 222.76 | 237.41 | 210.33 | 226.87 | 1,038,496 | 2.67 | 1.20% |
3 Months | 219.15 | 237.41 | 189.44 | 213.98 | 1,189,240 | 6.28 | 2.87% |
6 Months | 237.50 | 268.74 | 189.44 | 227.37 | 1,179,428 | -12.07 | -5.08% |
1 Year | 299.63 | 319.76 | 189.44 | 244.11 | 1,106,904 | -74.20 | -24.76% |
3 Years | 295.27 | 468.2499 | 187.16 | 264.21 | 1,233,748 | -69.84 | -23.65% |
5 Years | 226.05 | 468.2499 | 187.16 | 269.90 | 1,367,239 | -0.62 | -0.27% |
Biogen Description
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |